Epidemiology, species distribution, antifungal susceptibility, and outcome of Candidemia across five sites in Italy and Spain

Journal of Clinical Microbiology

Volumn 51, Issue 12, 2013, Pages 4167-4172

  Bassetti, Matteo ^a   Merelli, Maria ^a   Righi, Elda ^a   Diaz Martin, Ana ^b   Rosello, Eva Maria ^c   Luzzati, Roberto ^d   Parra, Anna ^c   Trecarichi, Enrico Maria ^e   Sanguinetti, Maurizio ^e   Posteraro, Brunella ^e   Garnacho Montero, Jose ^b   Sartor, Assunta ^a   Rello, Jordi ^c   Tumbarello, Mario ^e  

^a S Maria Hospital   (Italy)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; COMORBIDITY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FUNGUS IDENTIFICATION; HUMAN; INTENSIVE CARE UNIT; ITALY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPAIN; SPECIES DISTRIBUTION; TEACHING HOSPITAL; TERTIARY CARE CENTER;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; FEMALE; HOSPITALS, TEACHING; HUMANS; INCIDENCE; ITALY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SPAIN; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84889812043     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01998-13     Document Type: Article

References (41)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
2. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser MP, Täuber MG, Pittet D, Fungal Infection Network of Switzerland. 2004. Epidemiology of candidaemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin. Infect. Dis. 38:311-320.
3. Asmundsdóttir LR, Erlendsdóttir H, Gottfredsson M. 2002. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J. Clin. Microbiol. 4:3489-3492.
4. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. 2005. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 41:1232-1239.
5. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O, AmarCand Study Group. 2009. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit. Care Med. 37: 1612-1618.
6. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. 2009. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 48:1695-1703.
7. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. 2006. Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents 27:359-366.
8. Almirante B, Rodríguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P, Fridkin SK, Morgan J, Rodriguez-Tudela JL, Warnock DW, Pahissa A, Barcelona Candidemia Project Study Group. 2005. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43:1829-1835.
9. Cisterna R, Ezpeleta G, Telleria O, Spanish Candidemia Surveillance Group. 2010. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J. Clin. Microbiol. 48: 4200-4206.
10. Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D. 2002. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 81:425-433.
11. Luzzati R, Amalfitano G, Lazzarini L, Soldani F, Bellino S, Solbiati M, Danzi MC, Vento S, Todeschini G, Vivenza C, Concia E. 2000. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis. 19:602-607.
12. Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C. 2006. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect. Dis. 6:21. doi:10.1186/1471-2334-6-21.
13. Bassetti M, Trecarichi EM, Righi E, Sanguinetti M, Bisio F, Posteraro B, Soro O, Cauda R, Viscoli C, Tumbarello M. 2007. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn. Microbiol. Infect. Dis. 58:325-331.
14. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. 2011. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 6(9):e24198. doi:10.1371/journal.pone.0024198.
15. Bassetti M, Ansaldi F, Nicolini L, Malfatto E, Molinari MP, Mussap M, Rebesco B, Bobbio Pallavicini F, Icardi G, Viscoli C. 2009. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J. Antimicrob. Chemother. 64:625-629.
16. Colombo AL, Nucci M, Salomao R, Branchini ML, Richtmann R, Derossi A, Wey SB. 1999. High rate of non-Albicans candidemia in Brazilian tertiary care hospitals. Diagn. Microbiol. Infect. Dis. 34:281-286.
17. Kett DH, Azoulay E, Echeverria PM, Vincent JL, Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. 2011. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit. Care Med. 39:665-670.
18. De Rosa FG, Trecarichi EM, Montrucchio C, Losito AR, Raviolo S, Posteraro B, Corcione S, Di Giambenedetto S, Fossati L, Sanguinetti M, Serra R, Cauda R, Di Perri G, Tumbarello M. 2012. Mortality in patients with early- or late-onset candidaemia. J. Antimicrob. Chemother. 68:927-935.
19. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, De Pauw B, Meunier F. 1999. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect Dis. 28:1071-1079.
20. Nguyen MH, Peacock JE, Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
21. Rocco TR, Reinsert SE, Simms HH. 2000. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch. Surg. 135:160-165.
22. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50:2846-2856.
24. Zilberberg MD, Shorr AF, Kollef MH. 2008. Secular trends in candidemia- related hospitalization in the United States, 2000 -2005. Infect. Control Hosp. Epidemiol. 29:978-980.
25. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. 2002. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 45:141-145.
26. Richet H, Roux P, Des Champs C, Esnault Y, Andremont A, French Candidemia Study Group. 2002. Candidemia in French hospitals: incidence rates and characteristics. Clin. Microbiol. Infect. 8:405-412.
27. Poikonen E, Lyytikäinen O, Anttila VJ, Koivula I, Lumio J, Kotilainen P, Syrjälä H, Ruutu P. 2010. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect. Dis. 10:312. doi:10.1186 /1471-2334-10-312.
28. Clark TA, Slavinski SA, Morgan J, Lott T, Arthington-Skaggs BA, Brandt ME, Webb RM, Currier M, Flowers RH, Fridkin SK, Hajjeh RA. 2004. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J. Clin. Microbiol. 42:4468-4472.
29. Lin MY, Carmeli Y, Zumsteg J, Flores EL, Tolentino J, Sreeramoju P, Weber SG. 2005. Prior antimicrobial therapy and risk for hospitalacquired Candida glabrata and Candida krusei fungemia: a case-casecontrol study. Antimicrob. Agents Chemother. 49:4555-4560.
30. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE, NIAID Mycoses Study Group. 2009. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643.
31. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. 2011. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008 -2009). Int. J. Antimicrob. Agents 38:65-69.
32. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. 1989. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev. Infect. Dis. 11:379-390.
33. Lockhart SR, Pham CD, Gade L, Iqbal N, Scheel CM, Cleveland AA, Whitney AM, Noble-Wang J, Chiller TM, Park BJ, Litvintseva AP, Brandt ME. 2013. Preliminary laboratory report of fungal infections associated with contaminated methylprednisolone injections. J. Clin. Microbiol. 51:2654-2661.
34. Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, Guzman-Blanco M, Santolaya ME, Thompson L, Sifuentes- Osornio J, Echevarria JI, Colombo AL, Latin American Invasive Mycosis Network. 2013. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 8(3):e59373. doi:10.1371/journal .pone.0059373.
35. Messer SA, Moet GJ, Kirby JT, Jones RN. 2009. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J. Clin. Microbiol. 47:1942-1946.
36. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45-50.
37. Doern L, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt A, Pfaller MA. 2002. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study. J. Clin. Microbiol. 40:1298-1302.
38. Dóczi I, Dósa E, Hajdú E, Nagy E. 2002. Aetiology and antifungal susceptibility of yeast bloodstream infections in a Hungarian university hospital between 1996 and 2000. J. Med. Microbiol. 51:677-681.
39. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. 1992. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. 15:414-421.
40. Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P. 2003. Candidemia in Finland, 1995-1999. Emerg. Infect. Dis. 9:985-990.
41. Bassetti M, Molinari MP, Mussap M, Viscoli C, Righi E. 2013. Candidaemia in internal medicine departments: the burden of a rising problem. Clin. Microbiol. Infect. 19:E281-E284. doi:10.1111/1469-0691.12155.